Correlations among Pain Severity, Functional Impairment and Clinical Symptoms in Fibromyalgia Rebecca L. Ross PhD, RN, PMHNP-BC, Assistant Professor

Background: Fibromyalgia (FM) Prevalence estimated at 2- 5% in the general population ( Wolfe et al.1995; Goldenberg et al., 2004; Lawrence et al., 2008) –3.4% in women –0.5% in men –90% women, 10% men Increases with age Survey of 2,596 US FM patients (Bennett et al., 2007) : –42.4% diagnosed by a rheumatologist –35.4% diagnosed by Family Practitioner or Internist Second most common disorder seen by rheumatologists (after OA)

Background: FM Burden Economic Impac t –$700 million direct costs in the US (Wolf et al., 1995) –$15.9 billion direct/indirect costs annually (Thorson, 1996) –U.S. Healthcare costs per FM patient annually average $10,199 (White et al., 2008) Co-morbid Major Depressive Disorder –30% Cross-sectional Prevalence (Epstein et al., 1999) –60% Lifetime Prevalence (Epstein et al., 1999) 3

FM Severity Related to Increased Costs France, total costs: €7900 = $9, –direct €910 = $11,46.34 –indirect €6990 = $8, Germany, total costs: €7256 = $ – direct €1765 = $ –indirect €5491 = $ Increased FM severity = Higher total costs (p = 0.003) (Winkelmann et al., 2011) 4

Background: Major Depressive Disorder (MDD) Prevalence and Burden: –2 nd leading cause of disability in people ≥5 years worldwide in US (WHO, 2012) –leading cause of morbidity in US (CDC, 2011) –9.1% lifetime prevalence, approx million Americans (CDC, 2011) 21% women, 13% men (Kessler et al., 2003) Economic Impact (Greenberg et al., 2003) –1990: $43 direct/indirect costs in US –2000: $52.9 direct/indirect costs in US

Depression- Morbidity Leading cause of disability (YLDs) in world 4th leading contributor to global burden of disease (DALYs) in 2000DALYs Currently, already the 2nd cause of DALYs in the age category years for both sexes combined By 2020, projected to reach 2nd place (DALYs) for all ages, both sexes (WHO, 2012)DALYs 6

Background: FM with Co-morbid MDD FM and Major Depressive Disorder both have a dysregulated HPA axis. (Neeck, 2000, 2002; Nemeroff, 1998; Gold et al., 2002; Tsigos & Chrousos, 2002; de Winter et al., 2003) Two specific subtypes of MDD have inverse biochemical marker levels. (Gold & Chrousos, 2002) –Atypical depressive episodes (20%-30% prev.) associated with low cortisol levels. –Melancholic depressive episodes (30% prev.) associated with increased cortisol levels.

Biochemical Markers of Depression Subtypes in Fibromyalgia Sample –Adult females with FM with or without Major Depressive Disorder (MDD) Setting –Recruited from a tertiary care University Rheumatology FM Clinic in the Pacific Northwest Sample Size n= 62 –FM no MDD n= 7 –FM/ADE n= 31 –FM/MDE n= 24 8

Methods: Psychometric Measures Beck Depression Inventory- II (Revised 1973) Tender-point / Cumulative Myalgic Scale (CMS) MDD Subtype Screening (DSM-IV) Hamilton Depression Rating Scale (HDRS) Flanagan’s Quality of Life Scale (QOLS) Jenkins Sleep Scale Fibromyalgia Impact Questionnaire (FIQ)

Statistical Analysis Pearson’s R binomial correlation analyses to examine relationships among: 1.Individual FM Symptoms: pain severity, stiffness, fatigue 2.Other clinical characteristics commonly related to FM: pain interference, depression, anxiety, sleep quality, quality of life 3. Functional Capacity physical impairment, functional capacity / overall impact of FM on daily life 10

Results: Pain Severity Pain severity (FIQ VAS) highly correlated with: –Physical Impairment(FIQ Subscale: r= 0.508; p<0.001) –Depression (HDRS: r= 0.612; p< 0.001) –Depression (FIQ VAS: r= 0.558; p< 0.001) –Fatigue (FIQ VAS: r= 0.681; p< 0.001) –Stiffness (FIQ VAS: r= 0.667; p< 0.001) Moderately correlated with: –Sleep (Flanagan’s: r= 0.488; p= 0.001) –Anxiety (FIQ VAS: r= 0.421; p= 0.001) 11

Results: Physical Impairment Physical Impairment (FIQ Subscale) highly correlated with: –Overall Burden of FM on Daily Life (FIQ Total Score: r= 0.658; p< 0.001) –Anxiety (FIQ VAS: r= 0.637; p< 0.001) –Fatigue (FIQ VAS: r= 0.681; p< 0.001) –Stiffness (FIQ VAS: r= 0.667; p< 0.001) Moderately correlated with: –Depression (HDRS-17: r= 0.459; p=< 0.001) Inversely correlated with: –Quality of Life (Flanagan’s: r= ; p< 0.001) 12

Results: Functional Capacity Overall Impact of FM on Daily Life (FIQ Total Score) highly correlated with: –Pain Severity (FIQ VAS: r= 0.808; p< 0.001) –Depression (FIQ VAS : r= 0.773; p< 0.001) –Depression (HDRS-17: r= 0.663; p=< 0.001) – Anxiety (FIQ VAS: r= 0.637; p< 0.001) –Fatigue (FIQ VAS: r= 0.757; p< 0.001) –Stiffness (FIQ VAS: r= 0.703; p< 0.001) Moderately with Sleep (Jenkins: r= 0.488; p= 0.001) Inversely with Quality of Life (r= ; p< 0.001) 13

Conclusions Findings highlight growing importance of patient- centered individualized treatment for both physical and psychological symptoms of FM. In this time of rising healthcare costs, the concept of systematically identifying which FM symptoms are the most bothersome to patients and focusing treatment accordingly is of special interest to the nursing profession. 14

Bibliography (To Be Added) 15

Brain Circuits of the Stress Response

Methods: Biological Measures Standard Dexamethasone Suppression Test (DST) protocol followed (Arana, 1987) Dexamethasone 1.5 mg taken orally at 2300 (14 hours) before the laboratory visit Combined DEX Suppression/ CRH Stimulation Test- standard protocol same as DST except: Acthrel (oCRH) 100 mcg given by IV push at 1502 hr. (Heuser et al., 1994) Plasma cortisol samples were drawn at 6 time points: 1445, 1500, 1530, 1545, 1600, 1615.

Clinical Characteristics: Post- hoc Analyses –Compared to the FM no MDD group, the FM/ADE & FM/MDE** groups had: –worse severity of FM symptoms –worst impact of FM symptoms on ability to function –poorer quality of life –poorer quality of sleep –The FM/MDE group had the most severe depression symptoms **There were no significant differences between the FM/ADE and FM/MDE groups except in depression severity. (Ross et al., 2010)